Interleukin-6 amplifies glucagon secretion: Coordinated control via the brain and pancreas

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 10, 2014, Pages E896-E905

  Barnes, Tammy M ^a   Otero, Yolanda F ^a   Elliott, Amicia D ^a   Locke, Alicia D ^a   Malabanan, Carlo M ^a   Coldren, Anastasia G ^a   Brissova, Marcela ^a   Piston, David W ^a   McGuinness, Owen P ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endotoxemia; Glucagon; Hypoglycemia; Inflammation; Interleukin 6

Indexed keywords

ADRENALIN; GLUCAGON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; INTERLEUKIN-6, MOUSE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRAIN; CATECHOLAMINERGIC SYSTEM; CHOLINERGIC SYSTEM; CONTROLLED STUDY; GLUCAGON RELEASE; HYPOGLYCEMIA; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; GLUCOSE CLAMP TECHNIQUE; METABOLISM; PANCREAS ISLET ALPHA CELL; PHYSIOLOGICAL STRESS; SECRETION (PROCESS);

ANIMALS; BRAIN; EPINEPHRINE; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE CLAMP TECHNIQUE; HYPOGLYCEMIA; INTERLEUKIN-6; ISLETS OF LANGERHANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; STRESS, PHYSIOLOGICAL; SYMPATHOMIMETICS;

EID: 84925060825     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00343.2014     Document Type: Article

References (57)

1. Anton AH, Sayre DF. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138: 360-375, 1962.
2. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55: 390-397, 2006.
3. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 179: 53-56, 1994.
4. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084-2089, 2002.
5. Beverly JL, De Vries MG, Bouman SD, Arseneau LM. Noradrenergic and GABAergic systems in the medial hypothalamus are activated during hypoglycemia. Am J Physiol Regul Integr Comp Physiol 280: R563-R569, 2001.
6. Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 99: 361-365, 1997.
7. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 44: 180-184, 1995.
8. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, Chen Z, Carr C, Jerome WG, Chen J, Baldwin HS, Nicholson W, Bader DM, Jetton T, Gannon M, Powers AC. Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 55: 2974-2985, 2006.
9. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190, 2005.
10. Chen C, Du J, Feng W, Song Y, Lu Z, Xu M, Li Z, Zhang Y. β-Adrenergic receptors stimulate interleukin-6 production through Epacdependent activation of PKCδ/p38 MAPK signalling in neonatal mouse cardiac fibroblasts. Br J Pharmacol 166: 676-688, 2012.
11. Chuang JC, Sakata I, Kohno D, Perello M, Osborne-Lawrence S, Repa JJ, Zigman JM. Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol Endocrinol 25: 1600-1611, 2011.
12. Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care 31: 1222-1223, 2008.
13. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 105: 13163- 13168, 2008.
14. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AM, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481- 1489, 2011.
15. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 8: 1254-1266, 2012.
16. Havel PJ, Mundinger TO, Taborsky GJ, Jr. Pancreatic sympathetic nerves contribute to increased glucagon secretion during severe hypoglycemia in dogs. Am J Physiol Endocrinol Metab 270: E20 -E26, 1996.
17. Havel PJ, Veith RC, Dunning BE, Taborsky GJ, Jr. Role for autonomic nervous system to increase pancreatic glucagon secretion during marked insulin-induced hypoglycemia in dogs. Diabetes 40: 1107-1114, 1991.
18. Helwig BG, Craig RA, Fels RJ, Blecha F, Kenney MJ. Central nervous system administration of interleukin-6 produces splenic sympathoexcitation. Auton Neurosci 141: 104-111, 2008.
19. Hirano T. Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci 86: 717-730, 2010.
20. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-E678, 2003.
21. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417-3427, 2005.
22. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789, 2003.
23. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311: 372-379, 2003.
24. Le Marchand SJ, Piston DW. Glucose suppression of glucagon secretion: metabolic and calcium responses from alpha-cells in intact mouse pancreatic islets. J Biol Chem 285: 14389-14398, 2010.
25. Macdonald IA, Lake DM. An improved technique for extracting catecholamines from body fluids. J Neurosci Methods 13: 239-248, 1985.
26. Maimone D, Cioni C, Rosa S, Macchia G, Aloisi F, Annunziata P. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J Neuroimmunol 47: 73-81, 1993.
27. McGuinness OP. Defective glucose homeostasis during infection. Annu Rev Nutr 25: 9-35, 2005.
28. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, York DA, Pinkney J. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86: 5864-5869, 2001.
29. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57: 3211-3221, 2008.
30. Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272: 22570-22575, 1997.
31. Norris JG, Benveniste EN. Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 45: 137-145, 1993.
32. Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, Narazaki M, Tanaka T. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70: 1164-1165, 2011.
33. Olesen J, Hougard K, Hertz M. Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. Stroke 9: 344-349, 1978.
34. Paranjape SA, Chan O, Zhu W, Horblitt AM, McNay EC, Cresswell JA, Bogan JS, McCrimmon RJ, Sherwin RS. Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 59: 1521-1527, 2010.
35. Pedersen BK, Steensberg A, Schjerling P. Exercise and interleukin-6. Curr Opin Hematol 8: 137-141, 2001.
36. Perez DM, Papay RS, Shi T. alpha1-Adrenergic receptor stimulates interleukin-6 expression and secretion through both mRNA stability and transcriptional regulation: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. Mol Pharmacol 76: 144-152, 2009.
37. Rocheleau JV, Walker GM, Head WS, McGuinness OP, Piston DW. Microfluidic glucose stimulation reveals limited coordination of intracellular Ca2+ activity oscillations in pancreatic islets. Proc Natl Acad Sci USA 101: 12899-12903, 2004.
38. Rocheleau JV, Walker GM, Head WS, McGuinness OP, Piston DW. Microfluidic glucose stimulation reveals limited coordination of intracellular Ca2+ activity oscillations in pancreatic islets. Proc Natl Acad Sci USA 101: 12899-12903, 2004.
39. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777-45784, 2003.
40. Sandler S, Bendtzen K, Eizirik DL, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126: 1288-1294, 1990.
41. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391-3399, 2002.
42. Shimizu H, Ohtani K, Kato Y, Mori M. Interleukin-6 increases insulin secretion and preproinsulin mRNA expression via Ca2+-dependent mechanism. J Endocrinol 166: 121-126, 2000.
43. Sorensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, Shulman GI. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55: 2843-2848, 2006.
44. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)- Potsdam Study. Diabetes 52: 812-817, 2003.
45. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, Brandon NJ. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry 2: e199, 2012.
46. Szepietowska B, Zhu W, Chan O, Horblitt A, Dziura J, Sherwin RS. Modulation of beta-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia. Diabetes 60: 3154-3158, 2011.
47. Taborsky GJ, Jr., Mundinger TO. Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 153: 1055-1062, 2012.
48. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab 13, Suppl 1: 82-88, 2011.
49. Tong Q, Ye C, McCrimmon RJ, Dhillon H, Choi B, Kramer MD, Yu J, Yang Z, Christiansen LM, Lee CE, Choi CS, Zigman JM, Shulman GI, Sherwin RS, Elmquist JK, Lowell BB. Synaptic glutamate release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents hypoglycemia. Cell Metab 5: 383-393, 2007.
50. Tweedell A, Mulligan KX, Martel JE, Chueh FY, Santomango T, McGuinness OP. Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6. Metabolism 60: 92-98, 2011.
51. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122: 4-12, 2012.
52. Vallieres L, Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropinreleasing factor during endotoxemia. Endocrinology 140: 3890-3903, 1999.
53. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359-1367, 2001.
54. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature- onset obesity. Nat Med 8: 75-79, 2002.
55. Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab 296: E11-E21, 2009.
56. Ye S, Mozayeni P, Gamburd M, Zhong H, Campese VM. Interleukin- 1β and neurogenic control of blood pressure in normal rats and rats with chronic renal failure. Am J Physiol Heart Circ Physiol 279: H2786- H2796, 2000.
57. Zielinski MR, Dunbrasky DL, Taishi P, Souza G, Krueger JM. Vagotomy attenuates brain cytokines and sleep induced by peripherally administered tumor necrosis factor-α and lipopolysaccharide in mice. Sleep 36: 1227-1238, 1238A, 2013.